Such resistance development occurs with the commonly used tumor necrosis-alpha (TNFα) inhibitors for rheumatoid arthritis, which also have unpleasant side effects, and novel approaches with selective inducers of immune tolerance are under investigation [74]. The gene discussed is TNF; the disease is rheumatoid arthritis.